A province-level risk factor analysis of fluoroquinolone consumption patterns in Canada (2000-06)

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 9, 2010, Pages 2019-2027

  Glass, Shiona K ^a   Pearl, David L ^a   McEwen, Scott A ^a   Finley, Rita ^a,b  

^a UNIVERSITY OF GUELPH   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Antibiotic policy; Antibiotic usage; Influenza

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; NORFLOXACIN; OFLOXACIN; PRESCRIPTION DRUG; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL INFECTION; CANADA; DRUG INDICATION; DRUG USE; HUMAN; INFLUENZA; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PREDICTOR VARIABLE; RISK ASSESSMENT; RISK FACTOR; SEASONAL INFLUENZA; SEASONAL VARIATION; SOCIOECONOMICS; STREPTOCOCCUS PNEUMONIAE; SUMMER; WINTER;

EID: 77955592405     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq225     Document Type: Article

References (37)

1. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis 2005; 41: 118-21.
2. Pérez-Trallero E, Marimon JM, Iglesias L et al. Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerg Infect Dis 2003; 9: 1159-62.
3. Davidson R, Cavalcanti R, Brunton JL et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 747-50.
4. Bhavnani SM, Hammel JP, Jones RN et al. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumonia in the United States. Diagn Microbiol Infect Dis 2005; 51: 31-7.
5. Chen DK, McGeer A, deAzavedo JC et al. Decreased susceptibility of Streptococcus pneumonia to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233-9.
6. LeBlanc L, Pépin J, Toulouse K et al. Fluoroquinolones and risk for methicillin-resistant Staphylococcus aureus, Canada. Emerg Infect Dis 2006; 12: 1398-405.
7. Weber SG, Gold HS, Hooper DC et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003; 9: 1415-22.
8. MacDougall C, Harpe SE, Powell JP et al. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use. Emerg Infect Dis 2005; 11: 1197-204.
9. Polk RE, Johnson KCK, McClish D et al. Predicting hospital rates of fluoroquinolone resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 2004; 39: 497-503.
10. Lautenbach E, Fishman NO, Bilker WB et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002; 162: 2469-77.
11. Patrick DM, Hutchinson J. Antibiotic use and population ecology: how you can reduce your " resistance footprint" . CMAJ 2009; 180: 416-21.
12. Belongia EA, Schwartz B. Strategies for promoting judicious antimicrobial use by doctors and patients. BMJ 1998; 317: 668-71.
13. Mainous AG, Zoorob RJ, Oler MJ et al. Patient knowledge of upper respiratory infections: implications for antibiotic expectations and unnecessary utilization. J Fam Pract 1997; 45: 75-9.
14. Kozyrskyj AL, Dahl ME, Chateau DG et al. Evidence-based prescribing of antibiotics for children: role of socioeconomic status and physician characteristics. CMAJ 2004; 171: 139-45.
15. Vanden Eng J, Marcus R, Hadler JL et al. Consumer attitudes and use of antibiotics. Emerg Infect Dis 2003; 9: 1128-35.
16. Glass SK, Pearl DL, McEwen SA et al. A Canadian province-level risk factor analysis of human consumption patterns of individual antimicrobial drugs within the macrolide class (2000-2006). J Antimicrob Chemother 2010; 65: 148-55.
17. World Health Organization. Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atcddd/ (8 December 2008, date last accessed).
18. Government of Canada. Canadian Integrated Program for Antimicrobial Resistance Surveillance Report 2005. Guelph: Public Health Agency of Canada, 2007.
19. Statistics Canada 2008. Table 202-0701-Market, Total and After-tax Income, by Economic Family Type and Income Quintiles, 2006 Constant Dollars, Annual (Table), CANSIM (Database), Using E-STAT (Distributor). http://estat.statcan.ca/cgi-win/cnsmcgi.exe?Lang=E&ESTATFile=EStat\English\CII_1_E.htm&RootDir=ESTAT/ (9 July 2008, date last accessed).
20. Statistics Canada 2008. Table 202-0802-Persons in Low Income, Annual (Table), CANSIM (Database), Using E-STAT (Distributor). http://estat.statcan.ca/cgi-win/cnsmcgi.exe?Lang=E&ESTATFile=EStat\English\ CII_1_E.htm&RootDir=ESTAT/ (9 July 2008, date last accessed).
21. Statistics Canada 2008. Table 051-0005-Estimates of Population, Canada, Provinces and Territories, Quarterly (Persons), CANSIM (Database), Using E-STAT (Distributor). http://estat.statcan.ca/cgi-win/cnsmcgi.exe?Lang=E&ESTATFile=EStat\English\CII_1_E.htm&RootDir=ESTAT/ (9 July 2008, date last accessed).
22. Statistics Canada 2008. Table 282-0003-Labour Force Survey Estimates (LFS), by Educational Attainment, Sex and Age Group, Unadjusted for Seasonality, Monthly (Persons Unless Otherwise Noted) (Table), CANSIM (Database), Using E-STAT (Distributor). http://estat. statcan.ca/cgi-win/cnsmcgi.exe?Lang=E&ESTATFile=EStat\English\CII_1_E.htm&RootDir=ESTAT/ (9 July 2008, date last accessed).
23. Statistics Canada 2008. Table 282-0010-Labour Force Survey Estimates (LFS), by National Occupational Classification for Statistics (NOC-S) and Sex, Annual (Persons Unless Otherwise Noted) (Table), CANSIM (Database), Using E-STAT (Distributor). http://estat.statcan.ca/cgi-win/cnsmcgi.exe?Lang=E&ESTATFile=EStat\English\CII_1_E.htm&Root Dir=ESTAT/ (9 July 2008, date last accessed).
24. Doohoo I, Martin W, Stryhn H. Veterinary Epidemiologic Research. Charlottetown: AVC Inc., 2003.
25. Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003; 9: 1-9.
26. Zhanel GG, Ennis K, Vercaigne L et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002; 62: 13-59.
27. Kang SL, Rybak MJ, McGrath BJ et al. Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococus aureus in an in vitro infection model. Antimicrob Agents Chemother 1994; 38: 2702-9.
28. Leibovitz E. The use of fluoroquinolones in children. Curr Opin Pediatr 2006; 18: 64-70.
29. TM dataset. http://www.imshealth.com (9 July 2008, date last accessed).
30. Mamdani MM, Tu K, Austin PC et al. Influence of socioeconomic status on drug selection for the elderly in Canada. Ann Pharmacother 2002; 36: 804-8.
31. Foxman B, Somsel P, Tallman P et al. Urinary tract infections among women aged 40 to 65: behavioral and sexual risk factors. J Clin Epidemiol 2001; 54: 710-8.
32. Cohen S. Social status and susceptibility to respiratory infections. Ann NY Acad Sci 1999; 896: 246-53.
33. Hutchinson JM, Foley RN. Method of physician remuneration and rates of antibiotic prescription. CMAJ 1999; 160: 1013-7.
34. Huang ES, Stafford RS. National patterns in the treatment of urinary tract infections in women by ambulatory care physicians. Arch Intern Med 2002; 162: 41-7.
35. MacDougall C, Powell JP, Johnson CK et al. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005; 41: 435-40.
36. Lautenbach E, Larosa LA, Kasbekar N et al. Fluoroquinolone utilization in the emergency departments of academic medical centers. Arch Intern Med 2003; 163: 601-5.
37. Gilbert DN, Kohlhepp SJ, Slama KA et al. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin. Antimicrob Agents Chemother 2001; 45: 883-92.